Literature DB >> 14993032

Laparoscopic sentinel node procedure using a combination of patent blue and radiocolloid in women with endometrial cancer.

Emmanuel Barranger1, Annie Cortez, Dany Grahek, Patrice Callard, Serge Uzan, Emile Darai.   

Abstract

BACKGROUND: We assessed the feasibility of a laparoscopic sentinel node (SN) procedure based on the combined use of radiocolloid and patent blue labeling in patients with endometrial cancer.
METHODS: Seventeen patients (median age, 69 years) with endometrial cancer of stage I (16 patients) or stage II (1 patient) underwent a laparoscopic SN procedure based on combined radiocolloid and patent blue injected pericervically. After the SN procedure, all patients underwent complete laparoscopic pelvic lymphadenectomy and either laparoscopically assisted vaginal hysterectomy (16 patients) or laparoscopic radical hysterectomy (1 patient).
RESULTS: SNs (mean number per patient, 2.6; range, 1-4) were identified in 16 (94.1%) of the 17 patients. Macrometastases were detected in three SNs from two patients by hematoxylin and eosin staining. In three other patients, immunohistochemical analysis identified six micrometastatic SNs and one SN containing isolated tumor cells. No false-negative SN results were observed.
CONCLUSIONS: An SN procedure based on a combination of radiocolloid and patent blue is feasible in patients with early endometrial cancer. Combined use of laparoscopy and this SN procedure permits minimally invasive management of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993032     DOI: 10.1245/aso.2004.07.005

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Sentinel lymph node detection following the hysteroscopic peritumoural injection of 99mTc-labelled albumin nanocolloid in endometrial cancer.

Authors:  Marco Maccauro; Giovanni Lucignani; Gianluca Aliberti; Carlo Villano; Maria Rita Castellani; Eugenio Solima; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-30       Impact factor: 9.236

Review 2.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

3.  Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?

Authors:  Nadeem R Abu-Rustum; Fady Khoury-Collado; Neeta Pandit-Taskar; Robert A Soslow; Fanny Dao; Yukio Sonoda; Douglas A Levine; Carol L Brown; Dennis S Chi; Richard R Barakat; Mary L Gemignani
Journal:  Gynecol Oncol       Date:  2009-02-20       Impact factor: 5.482

4.  Controversies in surgical staging of endometrial cancer.

Authors:  R Seracchioli; S Solfrini; M Mabrouk; C Facchini; N Di Donato; L Manuzzi; L Savelli; S Venturoli
Journal:  Obstet Gynecol Int       Date:  2010-06-23

5.  Controversies in the management of endometrial carcinoma: an update.

Authors:  Mohamed K Mehasseb; John A Latimer
Journal:  Obstet Gynecol Int       Date:  2012-02-16

6.  The Reliability of Intraoperative Assessment on Predicting Tumor Size, Myometrial Invasion, and Cervical Involvement in Patients With a Preoperative Diagnosis of Complex Atypical Hyperplasia or (Clinical Stage I) Endometrial Cancer: A Prospective Cohort Study.

Authors:  Brentley Q Smith; Jonathan D Boone; Eric D Thomas; Taylor B Turner; Gerald McGwin; Amanda M Stisher; Charles A Leath; Lea Novak; Warner K Huh
Journal:  Am J Clin Oncol       Date:  2020-02       Impact factor: 2.787

7.  Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer.

Authors:  Hans Nagar; Nina Wietek; Richard J Goodall; Will Hughes; Mia Schmidt-Hansen; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2021-06-09

Review 8.  The sentinel node in gynaecological malignancies.

Authors:  J Balega; P O Van Trappen
Journal:  Cancer Imaging       Date:  2006-02-28       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.